Celsis was a leading international provider of innovative life-science products and laboratory services to the global pharmaceutical and consumer products industries. The company operated through three divisions: Rapid Detection – a global market leader in the manufacture of diagnostic kits used to test for microbial contamination in liquid products for the pharmaceutical, personal care, dairy and beverage industries; Analytical Services – a provider of outsourced laboratory services to pharmaceutical and consumer product manufacturers; In Vitro Technologies – a global market leader in the supply of cryo-preserved human liver cells for use in early-stage drug testing by pharmaceutical companies. The three divisions were sold to separate trade buyers through the course of the investment.

Fund Fund 2 and 3
Investment date September 2009
Deal type Public-to-private
Sector Biotech services
Exit date July 2015
Exit type Trade sales
Back to Realised investments
City and trees